問卷
此案目前為暫存狀態
編修至YYYY/MM/DD
不開放編輯功能
Find Division/Department
Tri-Service General Hospital
All Location
All Division/Department
篩選
Developmental Phase
Phase I
Phase I/II
Phase II
Phase II/III
Phase III
Phase IV
Others
Trial Status
Not yet recruiting
Active
Completed
Recruitment Status
Recruiting
Terminated
Stop recruiting
Suspended
Study ended
Trial scale
Multi-Regional Multi-Center
Taiwan Multiple Center
Taiwan Single Center
The expected start time interval of the test
Trial Applicant
Hospital/Foundation
Pharmaceutical/Biopharmaceutical company
Contract Research Organization
Important Roles
Asia Regional PI
Taiwan National PI
Chairman/Global PI
Steering Committee
Advisory board
None
Audit by Sponsors/CRO
Sponsors
CRO
Investigator-initiated trial(IIT)
Yes
Filters
Division of Others
下載
2025-10-01 - 2035-01-20
Condition/Disease
DFS as assessed by the trial administrator. DFS is defined as the time elapsed from randomization until tumor recurrence or death from any cause (whichever occurs earlier).
Test Drug
Imfinzi® KEYTRUDA® OPDIVO Tecentriq® Zongertinib (BI 1810631)
Participate Sites6Sites
Recruiting6Sites
2019-11-01 - 2026-12-31
2019-11-01 - 2022-12-31
Participate Sites5Sites
Recruiting4Sites
2021-04-01 - 2027-05-31
Participate Sites17Sites
Not yet recruiting17Sites
2012-04-01 - 2017-03-31
Participate Sites8Sites
Terminated8Sites
2022-03-01 - 2027-08-31
Participate Sites12Sites
Recruiting12Sites
2021-08-01 - 2024-11-01
Terminated1Sites
2018-01-15 - 2029-06-30
Participate Sites7Sites
2021-12-01 - 2026-12-31
Participate Sites2Sites
Recruiting2Sites
2020-10-01 - 2026-12-31
Not yet recruiting7Sites
Recruiting1Sites
全部
